Details

Autor(en) / Beteiligte

• Kumar, Sanjeev
• Patel, Anamika
• Lai, Lilin
• Chakravarthy, Chennareddy
• Valanparambil, Rajesh
• Reddy, Elluri Seetharami
• Gottimukkala, Kamalvishnu
• Davis-Gardner, Meredith E
• Edara, Venkata Viswanadh
• Linderman, Susanne
• Nayak, Kaustuv
• Dixit, Kritika
• Sharma, Pragati
• Bajpai, Prashant
• Singh, Vanshika
• Frank, Filipp
• Cheedarla, Narayanaiah
• Verkerke, Hans P
• Neish, Andrew S
• Roback, John D
• Mantus, Grace
• Goel, Pawan Kumar
• Rahi, Manju
• Davis, Carl W
• Wrammert, Jens
• Godbole, Sucheta
• Henry, Amy R
• Douek, Daniel C
• Suthar, Mehul S
• Ahmed, Rafi
• Ortlund, Eric
• Sharma, Amit
• Murali-Krishna, Kaja
• Chandele, Anmol

Titel

Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody

Ist Teil von

• Science advances, 2022-10, Vol.8 (40), p.eadd2032-eadd2032

Ort / Verlag

United States: American Association for the Advancement of Science

Erscheinungsjahr

2022

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• In this study, by characterizing several human monoclonal antibodies (mAbs) isolated from single B cells of the COVID-19-recovered individuals in India who experienced ancestral Wuhan strain (WA.1) of SARS-CoV-2 during early stages of the pandemic, we found a receptor binding domain (RBD)-specific mAb 002-S21F2 that has rare gene usage and potently neutralized live viral isolates of SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta, and Omicron sublineages (BA.1, BA.2, BA.2.12.1, BA.4, and BA.5) with IC ranging from 0.02 to 0.13 μg/ml. Structural studies of 002-S21F2 in complex with spike trimers of Omicron and WA.1 showed that it targets a conformationally conserved epitope on the outer face of RBD (class 3 surface) outside the ACE2-binding motif, thereby providing a mechanistic insights for its broad neutralization activity. The discovery of 002-S21F2 and the broadly neutralizing epitope it targets have timely implications for developing a broad range of therapeutic and vaccine interventions against SARS-CoV-2 variants including Omicron sublineages.